The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s)
- PMID: 15979222
- DOI: 10.1016/j.yrtph.2005.05.004
The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s)
Abstract
The no-observed-adverse-effect-level (NOAEL) is an important part of the non-clinical risk assessment. It is a professional opinion based on the design of the study, indication of the drug, expected pharmacology, and spectrum of off-target effects. There is no consistent standard definition of NOAEL. This is based, in part, on the varied definitions of what constitutes an adverse effect. Toxicologists, either investigating or reviewing, have not been consistent in defining an effect as either adverse or acceptable. The common definition of NOAEL, "the highest experimental point that is without adverse effect," serves us well in general discussions. It does not, however, address the interpretation of risk based on toxicologically relevant effects, nor does it consider the progression of effect with respect to duration and/or dose. This paper will discuss the issues and application of a functional definition of the NOAEL in toxicology evaluations.
Similar articles
-
The benchmark dose method--review of available models, and recommendations for application in health risk assessment.Crit Rev Toxicol. 2003;33(5):505-42. Crit Rev Toxicol. 2003. PMID: 14594105 Review.
-
A procedure for developing risk-based reference doses.Regul Toxicol Pharmacol. 2002 Apr;35(2 Pt 1):137-41. doi: 10.1006/rtph.2002.1533. Regul Toxicol Pharmacol. 2002. PMID: 12051999 Review.
-
Future of toxicology--low-dose toxicology and risk--benefit analysis.Chem Res Toxicol. 2006 Aug;19(8):977-81. doi: 10.1021/tx0601051. Chem Res Toxicol. 2006. PMID: 16918235
-
Procedures for calculating benchmark doses for health risk assessment.Regul Toxicol Pharmacol. 1998 Oct;28(2):150-64. doi: 10.1006/rtph.1998.1247. Regul Toxicol Pharmacol. 1998. PMID: 9927564 Review.
-
Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Food Chem Toxicol. 2008. PMID: 18328408 Review.
Cited by
-
Successful drug development despite adverse preclinical findings part 2: examples.J Toxicol Pathol. 2010 Dec;23(4):213-34. doi: 10.1293/tox.23.213. Epub 2010 Dec 16. J Toxicol Pathol. 2010. PMID: 22272032 Free PMC article.
-
Non-Lethal Dose-Response Models Replace Lethal Bioassays for Predicting the Hazard of Para-Aminopropiophenone to Australian Wildlife.Animals (Basel). 2023 Jan 29;13(3):472. doi: 10.3390/ani13030472. Animals (Basel). 2023. PMID: 36766361 Free PMC article.
-
Protective role of N-acetylcysteine (NAC) on human sperm exposed to etoposide.Basic Clin Androl. 2019 Feb 7;29:3. doi: 10.1186/s12610-018-0082-2. eCollection 2019. Basic Clin Androl. 2019. PMID: 30774957 Free PMC article.
-
Guidance for statistical design and analysis of toxicological dose-response experiments, based on a comprehensive literature review.Arch Toxicol. 2023 Oct;97(10):2741-2761. doi: 10.1007/s00204-023-03561-w. Epub 2023 Aug 12. Arch Toxicol. 2023. PMID: 37572131 Free PMC article.
-
Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects.Nat Commun. 2019 Apr 5;10(1):1579. doi: 10.1038/s41467-019-09407-3. Nat Commun. 2019. PMID: 30952858 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources